Agio Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 5.18 Cr
as on 23-10-2024
- Company Age 32 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 74.01 Cr
as on 23-10-2024
- Satisfied Charges ₹ 205.08 Cr
as on 23-10-2024
- Revenue 66.15%
(FY 2023)
- Profit 1772.06%
(FY 2023)
- Ebitda 278.54%
(FY 2023)
- Net Worth 28.91%
(FY 2023)
- Total Assets 3.47%
(FY 2023)
About Agio Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.18 Cr.
The company currently has active open charges totaling ₹74.01 Cr. The company has closed loans amounting to ₹205.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
Madhusudan Ruia, Raghav Ruia, and Mahendra Kumawat serve as directors at the Company.
- CIN/LLPIN
U24239MH1992PLC065031
- Company No.
065031
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Jan 1992
- Date of AGM
30 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Agio Pharmaceuticals Limited offer?
Agio Pharmaceuticals Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Common Disease Medicines, Cough Syrup, Anti Infective Agent, Vitamin & Multivitamin Injections, Vitamin B Complex Injection, Antihistamines, Phenylephrine Hcl Tablet, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Agio Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhusudan Ruia  | Managing Director | 24-Jan-1992 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Raghav Ruia | Whole-Time Director | 04-Oct-2019 | Current |
| Mahendra Kumawat | Whole-Time Director | 09-Sep-2020 | Current |
Financial Performance of Agio Pharmaceuticals.
Agio Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 66.15% increase. The company also saw a substantial improvement in profitability, with a 1772.06% increase in profit. The company's net worth Soared by an impressive increase of 28.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agio Pharmaceuticals?
In 2022, Agio Pharmaceuticals had a promoter holding of 94.86% and a public holding of 5.14%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Revive Pharmaceuticals Private LimitedActive 28 years 10 monthsMadhusudan Ruia and Mahendra Kumawat are mutual person
- Bhakti Enterprises LimitedActive 17 years 3 months
Madhusudan Ruia, Raghav Ruia and 1 more are mutual person
- Kimaya Property Private LimitedActive 15 years 4 months
Madhusudan Ruia and Mahendra Kumawat are mutual person
- Genome Pharmaceuticals And Chemicals Private LimitedActive 30 years 4 months
Mahendra Kumawat is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sbicap Trustee Company Limited Creation Date: 18 Mar 2024 | ₹65.69 Cr | Open |
Others Creation Date: 10 Nov 2023 | ₹5.10 M | Open |
Axis Bank Limited Creation Date: 21 Jul 2023 | ₹8.00 M | Open |
How Many Employees Work at Agio Pharmaceuticals?
Agio Pharmaceuticals has a workforce of 343 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agio Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agio Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
